Our Valuation Suggests Innate Pharma is Undervalued
-Innate’s Programs Could Achieve ~$5B in Peak Sales- -Two Clinical Programs to Start Phase 2 Soon- Report is Available for Download at: www.lifesciadvisors.com/clients/innate Innate Pharma (Euronext:...
View ArticleLifeSci Advisors Publishes Recent Physician Survey on Questcor’s Acthar Gel
Survey Suggests use of Acthar Gel will Increase Available for Download at http://lifesciadvisors.com/marketresearch/ NEW YORK, NY – October 8, 2012 – LifeSci Advisors, LLC, a leading provider of...
View ArticleProof-of-Concept ALX-0061 RA Data and Potential €448MM Merck Deal Sweetens...
-ALX-0061 Met the Efficacy Endpoint in RA Study- -24 Week Data Expected in 1Q13- Report is Available for Download at: www.lifesciadvisors.com/clients/ablynx Last Thursday, Ablynx NV (Euronext Brussels:...
View ArticleVeloxis Announces Strategic Agreement for Commercialization and Distribution...
-Chiesi Farmaceutici to Provide Up To $47.5 Million in Up-Front Payments and Milestones- Report is Available for Download at: www.lifesciadvisors.com/clients/veloxis On October 5, 2012, Veloxis...
View ArticleInnate Pharma Announces Positive IPH21 Phase 1 AML Trial Results That Support...
-Phase 2 AML Study to Begin by Year End- Report is Available for Download at: www.lifesciadvisors.com/clients/innate Innate Pharma (Euronext: IPH) is a leading company in the innate immunology space...
View ArticleMore Positive PEARL-SC Data; Anthera Moves Blisibimod Into Phase 3 for Lupus
-New Positive PEARL-SC Secondary Results Reported- -Phase 3 Development Strategy Validated by FDA- Report is Available for Download at: www.lifesciadvisors.com/clients/anthera Anthera Pharmaceuticals...
View ArticleIPH.PA: Phase 1 IPH21/Anti-PD1 Combo Study in Solid Tumors Announced by BMS
Report is Available for Download at: www.lifesciadvisors.com/clients/innate Previously, we discussed the IPH21 Phase 1 data that was reported by Innate Pharma and concluded that it justified further...
View ArticleAgreement Upgraded to Collaboration – Del Mar Now Has Worldwide Rights to...
-Expands Indications for VAL-083 and Creates Near-term Revenue Opportunity for Del Mar in Asia- -VAL-083 Active Against TKI Resistant Phenotypes- Report is Available for Download at:...
View ArticleAblynx Announces Research Collaboration With Algeta to Explore the...
Report is Available for Download at: www.lifesciadvisors.com/clients/ablynx Last Wednesday, Ablynx NV (Euronext Brussels: ABLX) announced that it has entered into a research collaboration with Algeta...
View ArticleLIFESCI ADVISORS INITIATES COVERAGE OF RXI PHARMACEUTICALS
RXI-109 has the Potential to Become the First FDA Approved Product for Scar Prevention and Reduction Available for Download at www.lifesciadvisors.com/clients/rxi/ NEW YORK, NY – November 28, 2012 –...
View ArticleLIFESCI ADVISORS INITIATES COVERAGE OF CYTOMEDIX, INC.
-Cytomedix Markets the AutoloGel System (Autologous Platelet Based Therapy for Wound Healing) and the Angel Concentrated Platelet Rich Plasma (cPRP) System- -Proprietary ALDH Bright Cell Therapeutics...
View ArticleLIFESCI ADVISORS INITIATES COVERAGE OF TIGENIX, NV
-Report Details the Potential of TiGenix’s Allogeneic, Adipose Derived Stem Cell Therapies- -TiGenix is a Leading Cell Therapy Company that Markets the only Cell Therapy Approved in Europe,...
View ArticleAblynx 2012 Recap
Report is Available for Download at: www.lifesciadvisors.com/clients/ablynx This Research Update reviews the progress of Ablynx (Euronext: ABLX.BR) in 2012. Ablynx is engaged in the discovery and...
View ArticleAnthera to host Event at 2013 JP Morgan Healthcare Conference to Highlight...
-Sunday, January 6, 2013 at 5:30 pm; Handlery Hotel- Report is Available for Download at: www.lifesciadvisors.com/clients/anthera Anthera Pharmaceuticals will host a teach-in event at the Handlery...
View ArticleThe Company has announced dosing of the first patient of a Phase 1 trial of...
Report is Available for Download at: www.lifesciadvisors.com/clients/lajolla La Jolla Pharmaceutical Company (OTCQB: LJPC) enters 2013 with a renewed focus on the development of treatments for kidney...
View ArticleLIFESCI ADVISORS INITIATES COVERAGE OF NAVIDEA BIOPHARMACEUTICALS
Report Cites Potential of Lymphoseek® for Lymphatic Mapping, which has an April 30, 2013 PDUFA Goal Date, and NAV4694 and NAV5001 for the diagnosis of Alzheimer’s and Parkinson’s, Respectively Report...
View ArticlePRIME Data Shows SFP Achieves 37% ESA Sparing; Meets Primary Study Endpoint
-Study Confirms Expectation of Achieving Primary Endpoint in Phase 3 CRUISE Efficacy Studies- Report is Available for Download at: www.lifesciadvisors.com/clients/rockwell Rockwell Medical just...
View ArticleExciting Scar Reduction Activity Observed in Two Phase 1 RXI-109 Clinical...
-37% Average Reduction in Scar Tissue Observed- Report is Available for Download at: www.lifesciadvisors.com/clients/rxi During the recent 2013 BIO CEO Conference, which took place in New York City,...
View ArticleAblnyx Announces 24-Week Results from the ALX-0061 Phase II Clinical Trial in...
-Strong Efficacy and Safety Profile for All Doses- Report is Available for Download at: www.lifesciadvisors.com/clients/ablynx On February 13, 2012, Ablynx (Euronext: ABLX.BR) announced positive...
View ArticleAnthera Announces Clinical Path for Blisibimod – Phase II Trial to Begin in...
Report is Available for Download at: www.lifesciadvisors.com/clients/anthera Anthera Pharmaceuticals announced a new clinical trial for blisibimod as a treatment for IgA nephropathy. Dr. Adrian Liew,...
View Article